Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

June 23, 2023
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

MindRhythm Announces First Patient Enrolled in Pivotal Study of Novel Harmony™ Device for Rapid Detection of Stroke

June 22, 2023
MindRhythm Inc, in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announced that the first patient has been enrolled in the pivotal portion of its HeadPulse for Ischemic Stroke Detection Prehospital Study (EPISODE-VS). EPISODE-VS is designed to validate that...

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

June 20, 2023
Congratulations to Charles Chiu, Joe DeRisi, Michael Wilson and the Delve Bio team on their $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II and joined by Section 32 and Google Ventures!  UCSF is happy to partner with this talented and experienced team of scientists and...

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epileps

June 20, 2023
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of new data from the open-label, single-arm, starting dose-level of its ongoing Phase I/II clinical trial of a one-time dose...

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

June 07, 2023
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Exai Bio's core technology is founded on UCSF research done by Hani Goodarzi, PhD.

Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection

June 04, 2023
Mission Bio today announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. UCSF Researcher Adam Abate, PhD, is the lead inventor. More

UCSF NewCo Vevo Therapeutics has been Selected to Join the AWS Startups Generative AI Accelerator

May 31, 2023
Only 21 leading startups in the Generative AI space (out of 1200+ companies) were selected to be in the inaugural #AWSGenAIAccelerator cohort. The Vevo team, which already enjoys the support of some of the most esteemed thought leaders in the space (their advisors Richard Socher, Bo Wang, Michael...

Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023

May 30, 2023
 Pionyr Immunotherapeutics, a company developing first-in-class Myeloid Tuning antibody therapeutics that enhance the body’s antitumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced today that PY159, a monoclonal antibody targeting TREM1 (triggering...

Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial

April 25, 2023
The success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0....

Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting

April 19, 2023
Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest tumors, in both training and validation cohorts. In the independent validation cohort, stage I sensitivity...